Mitochondrial changes in cidofovir therapy for BK virus nephropathy

G Talmon1, L D Cornell, D J Lager

  • 1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA. gtalmon@unmc.edu

Insights

Cidofovir treatment for Polyoma virus nephropathy may cause proximal tubular mitochondrial toxicity in renal transplant patients. These findings highlight potential adverse effects of nucleotide analog drugs.

Area of Science:

  • Nephrology
  • Virology
  • Toxicology

Background:

  • Polyoma (BK) virus nephropathy (BKVN) is a significant complication in renal transplant recipients.
  • Cidofovir, a nucleotide analog, is a common treatment for BKVN.
  • Proximal tubular toxicity, including mitochondrial abnormalities, is a known adverse effect of nucleotide analogs.

Purpose of the Study:

  • To investigate ultrastructural mitochondrial changes in proximal tubular cells of renal allograft biopsies from BKVN patients treated with cidofovir.
  • To compare mitochondrial morphology in biopsies before and after cidofovir treatment.

Main Methods:

  • Retrospective analysis of renal allograft biopsies.
  • Categorization of biopsies into: initial diagnosis (BD), post-cidofovir treatment (CT), and post-immunosuppression reduction (IR).
  • Electron microscopy was used to assess ultrastructural mitochondrial changes in 19 cases per group.

Main Results:

  • Mitochondrial abnormalities were observed in 31.5% of biopsies from patients receiving cidofovir treatment (CT group).
  • Observed changes ranged from diffuse swelling to profound morphologic alterations.
  • No similar mitochondrial abnormalities were detected in the initial diagnosis (BD) or immunosuppression reduction (IR) groups.

Conclusions:

  • Cidofovir treatment in BKVN patients is associated with proximal tubular mitochondrial alterations.
  • These findings support the hypothesis of mitochondrial toxicity induced by nucleotide analog drugs.
  • The study underscores the importance of monitoring for cidofovir-related nephrotoxicity.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...